(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time. Issue 4 (9th October 2021)

• Record Type: Journal Article
• Authors: Boothe, Katherine
• Is Part Of: Health economics, policy and law. Volume 16:Issue 4(2021)
• Page Start: 424
• Page End: 439
• Publication Date: 2021-10-09
• Subjects: Comparative qualitative analysis -- evidence-based policy -- health technology assessment -- legitimacy -- policy paradigms -- public and patient involvement; Medical economics -- Periodicals; Medical policy -- Periodicals; Medical laws and legislation -- Periodicals; 362.1
• DOI: 10.1017/S1744133121000013
• Languages: English
• ISSNs: 1744-1331

Abstract

Abstract: How do experts judge the legitimacy of technical policy processes, and do their ideas change as these processes are opened to other stakeholders and the public? This research examines the adoption of public and patient involvement in pharmaceutical assessment in Canada. It finds tensions between scientific legitimacy that prioritizes rigor and objectivity, and democratic legitimacy that values inclusion and a broader range of evidence. In response to policy change, experts incorporate new ideas about democratic inputs and processes, while maintaining scientific policy goals. The research responds to calls for more precise measurement of ideas and ideational change and more evaluation of public and patient involvement in health policy. It helps us understand the significance of, and limits to, ideational change among experts in health policy domains that are highly technical and publicly salient. Understanding the way democratic and scientific legitimacy are negotiated in policy decisions has a wide applicability in health, but is particularly relevant during a global pandemic when evidence is being generated rapidly, decisions must be made quickly, and these decisions have a significant, immediate effect on the lives of all citizens.